Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational StudyShigeru Kusumoto, Ryuzo Ueda, Eiji Tanaka et al.|Clinical Infectious Diseases|2015Cited by 149
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J. Sonneveld, Benjamin Maasoumy, Shao‐Ming Chiu et al.|Journal of Hepatology|2022Cited by 121
Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivationTakako Inoue, Yasuhito Tanaka, Shigeru Kusumoto et al.|Journal of Hepatology|2021Cited by 110
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)Milan J. Sonneveld, Benjamin Maasoumy, Jun Yong Park et al.|Clinical Gastroenterology and Hepatology|2020Cited by 103
Soluble MICA and a MICA Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular CarcinomaVinod Kumar, Koichi Matsuda, Paulisally Hau Yi Lo et al.|PLoS ONE|2012Cited by 94